Drug Trial Radar · NCT04572893
Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities
Last checked: Nov 20, 2026Latest source record: May 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
41
Actual
Start
Aug 4, 2020
Primary completion
Feb 22, 2024
Study completion Feb 22, 2024
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Oct 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 2a study is to establish safety and preliminary efficacy of treatment with danicamtiv in patients with primary dilated cardiomyopathy (DCM) due to MYH7 or TTN variants or other causalities.
Conditions
- Primary Familial Dilated Cardiomyopathy
Interventions
danicamtivDrug
Myosin activator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs) in Part ATime frame: From first dose to 30 days post last dose (Up to approximately 15 weeks)
- Number of Participants With Serious Adverse Events (SAEs) in Part ATime frame: From first dose to 30 days post last dose (Up to approximately 15 weeks)
- Number of Participants With Safety Laboratory Assessments by Intensity in Part ATime frame: From first dose to 14 days post last dose (Up to approximately 13 weeks)
- Number of Participants With Clinically Significant Changes in Physical Examinations in Part ATime frame: From first dose to 30 days post last dose (Up to approximately 15 weeks)
- Number of Participants With Clinically Significant Changes in Vital Signs in Part ATime frame: From first dose to 30 days post last dose (Up to approximately 15 weeks)
- Number of Participants With Clinically Significant Changes in 12-Lead ECG Recordings in Part ATime frame: From first dose to 30 days post last dose (Up to approximately 15 weeks)
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Intensity in Part ATime frame: From first dose to 14 days post last dose (Up to approximately 13 weeks)
Locations
19 sites in 4 countries. Site status is shown where the registry gives one.
Local Institution - 0007
La Jolla, California
Local Institution - 0010
Washington D.C., District of Columbia
Local Institution - 0009
Tampa, Florida
Local Institution - 0002
Chicago, Illinois
Local Institution - 0003
Boston, Massachusetts
Local Institution - 0005
Rochester, Minnesota
Local Institution - 0006
Cleveland, Ohio
Local Institution - 0019
Columbus, Ohio
Local Institution - 0001
Philadelphia, Pennsylvania
Local Institution - 0004
Charleston, South Carolina
Local Institution - 0008
Germantown, Tennessee
Local Institution - 0018
Austin, Texas
Local Institution - 0015
Würzburg, Germany
Local Institution - 0014
Heidelberg, Baden-Wurttemberg, Germany
Local Institution - 0012
A Coruña, Spain
Local Institution - 0011
El Palmar, Spain
Local Institution - 0013
Majadahonda, Spain
Local Institution - 0016
London, United Kingdom
Local Institution - 0017
Middlesex, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.